OBJECTIVES: Available data on economic impact of hip fractures in the U.K. are mostly derived from clinical trials or published before the year 2000; recent estimates are lacking.  This study examined healthcare resource usage, treatment and costs among patients with hip fracture in the U.K. METHODS: The study used data from the Clinical Practice Research Datalink (CPRD) linked to the Hospital Episode Statistics (HES). Adult patients hospitalised for hip fracture (ICD-10:  S72 or M84.4; admission date as index date between 1/1/2006—3/31/2011) and no previous hip fracture 7 days to 1 year pre- index, and computerised data available 1 year pre and 1 year post-index were identified in HES.  Hip fracture-related inpatient and outpatient visits and pharmaceutical treatments were estimated for pre- and post-index periods. Associated costs were calculated by multiplying resource units by official publicly available costs from the NHS perspective. RESULTS: A total of 8,028 hip fracture patients were identified (mean age 79; 27% age 85+; 75.8% female; mean Charlson comorbidity index score 2.1). The most common comorbidities were osteoarthritis (42%), pulmonary disease (25%), and renal disease (23%). Pre-index, average resource use per patient included 1 inpatient stay (mean 5.7 days), 7.4 General surgery visits, 4.4 blood tests, and 0.76 General Practice phone consults. Average overall costs pre-index were £3122.  For the index hospitalisation, mean length-of-stay and costs were 19.5 days and £14223, respectively; 18% were discharged to another hospital; and 39% and 5% had partial or total hip arthroplasty procedures performed. Post-index frequent medications included acetaminophen (56%), opioids (46%), and bisphosphonates (46%); 51% had hospital stays; and 5.7% had subsequent hip fractures.  Average post-index overall costs were £7359. CONCLUSIONS: Our study provides recent estimates of resource usage, treatment and costs among U.K. hip fracture patients. This information can be useful in burden of illness and economic analyses.